Last close As at 06/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Research: Industrials
Carbios’s H119 results confirmed that the business is on a sound financial footing and continues to make progress towards the commercialisation of its technology. Commercial revenues from Carbiolice are scheduled to commence in 2020 and licences for its PET recycling technology are expected to be granted by 2023. Our current DCF-based valuation is €13/share.
Written by
Carbios |
A productive and active H119 |
H119 results |
Industrial support services |
30 September 2019 |
Share price performance
Business description
Next events
Analyst
Carbios is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||
Carbios’s H119 results confirmed that the business is on a sound financial footing and continues to make progress towards the commercialisation of its technology. Commercial revenues from Carbiolice are scheduled to commence in 2020 and licences for its PET recycling technology are expected to be granted by 2023. Our current DCF-based valuation is €13/share.
Year end |
Revenue (€m) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/17 |
1.0 |
(4.6) |
(0.86) |
0.0 |
N/A |
N/A |
12/18 |
1.1 |
(4.3) |
(0.67) |
0.0 |
N/A |
N/A |
12/19e |
1.2 |
(4.8) |
(0.60) |
0.0 |
N/A |
N/A |
12/20e |
1.7 |
(4.0) |
(0.42) |
0.0 |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Comfortable cash position
H119 results from Carbios appear on track to meet our FY19 forecasts. Revenues of €0.7m were slightly ahead of the run rate required to meet our FY19 projection of €1.2m. Lower than anticipated operating costs of €2.72m (FY19e: €5.85m) were offset by a smaller than expected tax credit of €0.3m (FY19e: €1.34m) to produce an H1 net loss of €1.71m (FY19 forecast net loss of €3.45m). Net cash consumption in H1 was €1.8m and as at 30 June Carbios’s net cash position was €3.4m before the proceeds of the equity issue (€13.8m (net) received in July). We expect capex to increase in H2 as Carbios begins construction of its PET recycling demonstration plant. However, with up to maximum of a further €4.1m of non-dilutive funding secured in H1 from SGPI, Carbios believes it should be able to cover its financial needs ‘beyond the next 24 months’. Our forecasts are unchanged.
Scientific and commercial advances
H1 saw Carbios continue with its progress towards commercialisation. As a result of a co-development agreement signed with Novozymes in H1, Carbios has secured the supply of enzymes for the industrialisation of its Carbiolice technology, scheduled for 2020 (initially films and carrier bags). In H1, Carbios also announced that it had produced the first PET bottles made with 100% Purified Terephthalic Acid (rPTA) and signed up Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe, (in addition to L’Oréal) to its PET Consortium to industrialise its PET technology. Construction of the PET recycling demonstration plant is expected to be followed by granting its first commercial licences by 2023.
Valuation: DCF indicative valuation of €13/share
Despite the uncertainties surrounding long-term revenue projections, we continue to believe that a DCF-based valuation remains the most appropriate valuation tool. Our DCF-based approach indicates a valuation of €13/share. The current market valuation reflects a 50% probability of our projections being achieved.
Exhibit 1: Financial summary
|
€m |
2014 |
2015 |
2016 |
2017 |
2018 |
2019e |
2020e |
Year end December 31st |
|
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
INCOME STATEMENT |
|
|
|
|
|
|
|
|
Revenue |
|
0.66 |
0.84 |
8.87 |
0.98 |
1.08 |
1.22 |
1.73 |
Operating Expenses |
|
(3.95) |
(4.73) |
(5.11) |
(5.39) |
(5.02) |
(5.60) |
(5.35) |
EBITDA (norm) |
|
(3.28) |
(3.90) |
3.76 |
(4.41) |
(3.94) |
(4.38) |
(3.62) |
Depreciation |
|
(0.08) |
(0.17) |
(0.21) |
(0.24) |
(0.30) |
(0.25) |
(0.25) |
Reported Operating Profit |
|
(3.36) |
(4.06) |
3.55 |
(4.65) |
(4.24) |
(4.63) |
(3.87) |
Net Interest |
|
0.05 |
0.08 |
0.08 |
0.02 |
(0.03) |
(0.16) |
(0.15) |
Profit before tax (reported) |
|
(3.32) |
(3.98) |
3.63 |
(4.63) |
(4.26) |
(4.79) |
(4.03) |
Reported tax |
|
1.09 |
0.94 |
1.32 |
0.70 |
1.19 |
1.34 |
1.12 |
Profit after tax (reported) |
|
(2.23) |
(3.05) |
4.95 |
(3.93) |
(3.07) |
(3.45) |
(2.90) |
Extraordinary gain or loss |
|
0.02 |
(0.02) |
(0.03) |
(0.01) |
(0.04) |
0.00 |
0.00 |
Net income (reported) |
|
(2.21) |
(3.07) |
4.92 |
(3.94) |
(3.11) |
(3.45) |
(2.90) |
|
|
|
|
|
|
|
|
|
Basic average number of shares outstanding (m) |
|
3.75 |
3.78 |
3.85 |
4.57 |
4.62 |
5.78 |
6.90 |
EPS - basic reported (€) |
|
(0.59) |
(0.81) |
1.28 |
(0.86) |
(0.67) |
(0.60) |
(0.42) |
Dividend (c) |
|
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
|
|
|
|
|
|
|
|
Revenue growth (%) |
|
-26.2% |
26.1% |
959.7% |
-88.9% |
10.2% |
12.5% |
41.7% |
Normalized EBITDA Margin (%) |
|
N/A |
N/A |
42.4% |
N/A |
N/A |
N/A |
N/A |
Normalized operating margin (%) |
|
N/A |
N/A |
40.0% |
N/A |
N/A |
N/A |
N/A |
|
|
|
|
|
|
|
|
|
BALANCE SHEET |
|
|
|
|
|
|
|
|
Total Current Liabilities |
|
0.67 |
0.91 |
1.17 |
2.26 |
3.40 |
4.58 |
4.38 |
Accounts payable |
|
0.20 |
0.34 |
0.49 |
1.43 |
1.06 |
1.12 |
1.02 |
Other current liabilities |
|
0.47 |
0.57 |
0.67 |
0.83 |
2.34 |
3.46 |
3.36 |
Total Non-Current Liabilities |
|
1.95 |
3.01 |
3.15 |
3.71 |
3.71 |
3.71 |
8.71 |
Debt/Repayable advances |
|
1.95 |
3.01 |
3.15 |
3.71 |
3.71 |
3.71 |
8.71 |
Total Liabilities |
|
2.62 |
3.92 |
4.32 |
5.97 |
7.11 |
8.29 |
13.09 |
|
|
|
|
|
|
|
|
|
Total Shareholders Equity |
|
11.12 |
8.13 |
13.11 |
14.55 |
12.04 |
22.37 |
19.47 |
Common stock / Capital |
|
2.63 |
2.65 |
2.68 |
3.20 |
3.26 |
3.26 |
3.26 |
Additional paid-in capital / Share premium |
|
13.65 |
13.70 |
13.74 |
18.59 |
19.13 |
32.91 |
32.91 |
Retained earnings |
|
(2.96) |
(5.17) |
(8.24) |
(3.32) |
(7.26) |
(10.37) |
(13.82) |
Other reserves and surplus |
|
(2.21) |
(3.05) |
4.94 |
(3.94) |
(3.10) |
(3.44) |
(2.89) |
Total liabilities and equity |
|
13.73 |
12.04 |
17.44 |
20.52 |
19.15 |
30.66 |
32.56 |
Total assets |
|
13.73 |
12.04 |
17.44 |
20.52 |
19.15 |
30.66 |
32.56 |
Total current assets |
|
12.64 |
10.38 |
6.16 |
9.17 |
6.69 |
12.56 |
4.68 |
Cash and cash equivalents |
|
11.10 |
9.01 |
3.99 |
7.55 |
5.15 |
11.46 |
3.34 |
Accounts receivable |
|
1.40 |
1.22 |
1.95 |
1.46 |
1.48 |
0.74 |
0.95 |
Inventories |
|
0.02 |
0.01 |
0.02 |
0.01 |
0.02 |
0.32 |
0.29 |
Prepaid expenses |
|
0.12 |
0.13 |
0.22 |
0.15 |
0.04 |
0.04 |
0.10 |
Total Non-Current Assets |
|
1.09 |
1.67 |
11.28 |
11.35 |
12.46 |
18.10 |
27.88 |
Property Plant and equipment, net |
|
0.74 |
1.25 |
1.21 |
1.11 |
0.97 |
4.34 |
11.73 |
Other intangible assets |
|
0.13 |
0.23 |
0.37 |
0.57 |
0.69 |
0.76 |
0.85 |
Other non-current assets |
|
0.22 |
0.19 |
9.70 |
9.68 |
10.80 |
13.00 |
15.30 |
|
|
|
|
|
|
|
|
|
CASH FLOW |
|
|
|
|
|
|
|
|
Cash Flow from Operations |
|
|
|
|
|
|
|
|
Net income (loss) |
|
(2.21) |
(3.07) |
4.92 |
(3.94) |
(3.11) |
(3.45) |
(2.90) |
Depreciation and Amortization |
|
0.07 |
0.17 |
0.22 |
0.23 |
0.33 |
0.25 |
0.25 |
Other items |
|
(1.36) |
0.39 |
(0.51) |
1.49 |
(0.29) |
1.61 |
(0.44) |
|
|
(3.50) |
(2.52) |
4.64 |
(2.22) |
(3.08) |
(1.59) |
(3.09) |
Cash Flow from Investing |
|
|
|
|
|
|
|
|
Purchases of fixed assets |
|
(0.85) |
(0.79) |
(0.30) |
(0.33) |
(0.30) |
(3.69) |
(7.73) |
Other Investing Activities |
|
(0.02) |
0.00 |
(9.53) |
0.02 |
(1.14) |
(2.20) |
(2.30) |
Net cash used in investing activities |
|
(0.87) |
(0.79) |
(9.83) |
(0.31) |
(1.44) |
(5.89) |
(10.03) |
Cash Flow from Financing |
|
|
|
|
|
|
|
|
Change in Debt |
|
0.15 |
0.07 |
(0.04) |
(0.05) |
1.52 |
0.00 |
5.00 |
Change in Capital Stock |
|
0.17 |
0.06 |
0.07 |
5.38 |
0.60 |
13.79 |
0.00 |
Other Financing Activities |
|
0.55 |
1.08 |
0.14 |
0.77 |
0.00 |
0.00 |
0.00 |
|
|
0.87 |
1.22 |
0.17 |
6.09 |
2.12 |
13.79 |
5.00 |
Net Changes in Cash and Cash Equivalent |
|
(3.50) |
(2.09) |
(5.02) |
3.56 |
(2.40) |
6.31 |
(8.12) |
Effect of Exchange Rates On Cash |
|
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
Cash and Cash Equivalents - Beginning |
|
14.60 |
11.10 |
9.01 |
3.99 |
7.55 |
5.15 |
11.46 |
Cash and Cash Equivalents - End |
|
11.10 |
9.01 |
3.99 |
7.55 |
5.15 |
11.46 |
3.34 |
Source: Company accounts, Edison Investment Research
|
|
Research: TMT
Osirium won a number of new customers and saw a 100% renewal rate in H119. It has signed up its first customer for the recently launched privileged process automation solution and is due to launch its first endpoint privilege management solution in Q4. With a broader product range, it has the opportunity to win new customers in the wider privileged access security market and cross-sell to its existing customer base.